Solid Tumors Phase 1 clinical trials

Explore recruiting solid tumors phase 1 clinical trials.

Recruiting solid tumors phase 1 studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Solid Tumors Phase 1 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

Spain, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Denmark, Poland, Spain, Sweden, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)

Spain, France, Belgium, Hungary, Romania, Portugal +2 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Sweden, Poland, Romania, Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Solid Tumors Phase 1 trials by city

Solid Tumors Phase 1 in Toronto Solid Tumors Phase 1 in Vancouver Solid Tumors Phase 1 in Montreal Solid Tumors Phase 1 in Calgary Solid Tumors Phase 1 in Edmonton Solid Tumors Phase 1 in Ottawa Solid Tumors Phase 1 in Winnipeg Solid Tumors Phase 1 in Quebec City Solid Tumors Phase 1 in Hamilton Solid Tumors Phase 1 in Kitchener Solid Tumors Phase 1 in London Solid Tumors Phase 1 in Halifax Solid Tumors Phase 1 in New York Solid Tumors Phase 1 in Los Angeles Solid Tumors Phase 1 in Chicago Solid Tumors Phase 1 in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease